BridgeBio Pharma, Inc. has announced that 28 abstracts concerning acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM)—comprising 12 new posters, seven oral presentations, and nine encore posters—will be presented at the XX International Symposium on Amyloidosis (ISA) 2026, scheduled for November 15-18, 2026, in Montevideo, Uruguay. According to the company, these presentations reinforce acoramidis as a primary first-line treatment choice for patients suffering from ATTR-CM, highlighting its profile as an orally administered, selective small molecule achieving near-complete stabilization of transthyretin (TTR) at or above 90%.
Bayer, which serves as BridgeBio's exclusive European licensing partner for acoramidis, is set to share five new presentations. Among these is real-world evidence originating from Germany comparing acoramidis to tafamidis regarding oral diuretic intensification, which serves as a marker for outpatient worsening heart failure.
Acoramidis has received regulatory approvals under multiple trade names globally. In the United States and Singapore via the Health Sciences Authority, it is approved as Attruby®. In other regions, including the European Union under the European Medicines Agency, Japan via the Pharmaceuticals and Medical Devices Agency, Switzerland through Swissmedic, the United Kingdom via the Medicines and Healthcare Products Regulatory Agency, Brazil through ANVISA, and Australia via the Therapeutic Goods Administration, it is authorized under the trade name BEYONTTRA®. All associated product labels specify near-complete stabilization of TTR.
The presentations scheduled during the symposium cover various analyses from the ATTRibute-CM trial, real-world studies, and open-label extension findings. Topics include safety and efficacy profiles in CKD stage 4 patients presented by Prem Soman, M.D. of the University of Pittsburgh Medical Center, background RAAS inhibitor impacts, and estimated glomerular filtration rate (eGFR) changes following treatment initiation analyzed across patient subgroups with and without atrial fibrillation or diabetes, as well as wild-type and variant ATTR-CM phenotypes. Additional presentations examine cardiorenal function, early time-to-benefit reductions in heart failure events, anchored matching-adjusted indirect comparisons against tafamidis, national VA cohort patterns, and economic health plan analyses.
Regarding approved indications, Attruby is indicated as a transthyretin stabilizer for treating cardiomyopathy in adults with wild-type or variant transthyretin-mediated amyloidosis to reduce cardiovascular-related deaths and hospitalizations. Important safety information notes that diarrhea (11.6% compared to 7.6% for placebo) and upper abdominal pain (5.5% compared to 1.4% for placebo) were reported in clinical trials. Most adverse reactions were mild and resolved without requiring drug discontinuation, with discontinuation rates due to adverse events remaining comparable between Attruby and placebo groups at 9.3% and 8.5%, respectively.
